2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center discusses intensity-modulated radiation therapy (IMRT) for patients with gynecologic cancers.
Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center discusses intensity-modulated radiation therapy (IMRT) for patients with gynecologic cancers.
Among patients who had standard radiation, almost 10% of them had trouble controlling bowel movements, whereas this occurred in only 2% of the patients who had IMRT. According to Klopp, it was surprising how severe the patient experience was.
The community is learning more about patient-reported outcomes that it is more sensitive to many forms of toxicity than physician-reported toxicity, explains Klopp.